Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNTA Genenta Science	$3.40 +6.3%	$3.68	$2.74 ▼ $7.28	$58.53M	0.62	4,396 shs	3,738 shs
IMMP Prima BioMed	$1.72 -0.6%	$1.70	$1.32 ▼ $2.72	$253.94M	1.66	77,517 shs	28,701 shs
MREO Mereo BioPharma Group	$1.71 -1.2%	$2.22	$1.47 ▼ $5.02	$275.07M	0.47	1.90 million shs	899,304 shs
SCPH scPharmaceuticals	$4.95 +3.6%	$4.53	$1.94 ▼ $6.28	$254.77M	0.4	375,224 shs	616,237 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNTA Genenta Science	+6.25%	-10.17%	-10.64%	-20.00%	-23.77%
IMMP Prima BioMed	-0.58%	-4.97%	+5.52%	-15.27%	-20.37%
MREO Mereo BioPharma Group	-1.16%	+8.23%	0.00%	-23.66%	-56.71%
SCPH scPharmaceuticals	+3.56%	-1.20%	+12.76%	+53.73%	+3.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNTA Genenta Science	2.7987 of 5 stars	3.5	3.0	0.0	3.8	1.7	0.0
IMMP Prima BioMed	1.4686 of 5 stars	3.5	1.0	0.0	2.7	0.0	0.0
MREO Mereo BioPharma Group	2.0481 of 5 stars	3.6	1.0	0.0	3.0	1.7	0.0
SCPH scPharmaceuticals	4.4737 of 5 stars	3.5	5.0	4.2	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNTA Genenta Science	3.00	Buy	$25.00	635.29% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	306.98% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.20	321.05% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	182.83% Upside

Current Analyst Ratings Breakdown

Latest GNTA, MREO, SCPH, and IMMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/10/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $5.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNTA Genenta Science	N/A	N/A	N/A	N/A	$0.74 per share	N/A
IMMP Prima BioMed	$5.14M	49.12	N/A	N/A	$1.05 per share	1.64
MREO Mereo BioPharma Group	$10M	27.19	N/A	N/A	$0.34 per share	5.03
SCPH scPharmaceuticals	$36.33M	7.26	N/A	N/A	($0.40) per share	-12.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNTA Genenta Science	-$9.64M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-80.00%	-66.94%	N/A
SCPH scPharmaceuticals	-$85.15M	-$1.81	N/A	N/A	N/A	-183.55%	-1,647.86%	-71.76%	N/A

Latest GNTA, MREO, SCPH, and IMMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$7.80 million	$0.50 million
8/7/2025	Q2 2025	SCPH scPharmaceuticals	-$0.30	-$0.34	-$0.04	-$0.34	$15.41 million	$16.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNTA Genenta Science	N/A	6.89	6.89
IMMP Prima BioMed	N/A	18.86	N/A
MREO Mereo BioPharma Group	N/A	8.13	8.92
SCPH scPharmaceuticals	3.86	3.85	3.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNTA Genenta Science	15.13%
IMMP Prima BioMed	2.32%
MREO Mereo BioPharma Group	62.83%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
GNTA Genenta Science	28.99%
IMMP Prima BioMed	3.07%
MREO Mereo BioPharma Group	5.50%
SCPH scPharmaceuticals	4.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable
IMMP Prima BioMed	2,021	146.79 million	142.28 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
SCPH scPharmaceuticals	30	53.30 million	50.75 million	Optionable

GNTA, MREO, SCPH, and IMMP Headlines

Recent News About These Companies

scPharmaceuticals receives Notices of Allowance from USPTO for SCP-111

August 14 at 2:28 PM | msn.com

scPharmaceuticals Q2 2025 Earnings Call Highlights Growth

August 14 at 9:26 AM | theglobeandmail.com

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

August 14 at 8:30 AM | globenewswire.com

scPharmaceuticals management to meet with Craig-Hallum

August 12 at 6:48 PM | msn.com

scPharmaceuticals, Inc. (NASDAQ:SCPH) Shares Acquired by King Luther Capital Management Corp

August 12 at 6:03 AM | marketbeat.com

Wall Street Zen Upgrades scPharmaceuticals (NASDAQ:SCPH) to "Hold"

August 10, 2025 | marketbeat.com

H.C. Wainwright Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)

August 9, 2025 | theglobeandmail.com

scPharmaceuticals (NASDAQ:SCPH) Upgraded to Hold at Wall Street Zen

August 9, 2025 | americanbankingnews.com

SCPH Revenue Up 99%

August 9, 2025 | aol.comA

ScPharmaceuticals anticipates meaningful Q3 nephrology contribution as FUROSCIX shipments rise 45% in Q2 2025

August 9, 2025 | msn.com

scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | globenewswire.com

Shareholders in scPharmaceuticals (NASDAQ:SCPH) are in the red if they invested five years ago

August 5, 2025 | uk.finance.yahoo.com

scPharmaceuticals (SCPH) to Release Earnings on Thursday

August 5, 2025 | marketbeat.com

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

July 31, 2025 | globenewswire.com

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

July 25, 2025 | zacks.com

scPharmaceuticals, Inc. (NASDAQ:SCPH) Shares Sold by AIGH Capital Management LLC

July 22, 2025 | marketbeat.com

With 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interest

June 12, 2025 | finance.yahoo.com

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

May 22, 2025 | seekingalpha.com

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 16, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA, MREO, SCPH, and IMMP Company Descriptions

Genenta Science NASDAQ:GNTA

$3.40 +0.20 (+6.25%)

Closing price 08/14/2025 02:57 PM Eastern

Extended Trading

$3.40 0.00 (0.00%)

As of 08/14/2025 06:56 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Prima BioMed NASDAQ:IMMP

$1.72 -0.01 (-0.58%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.69 -0.03 (-1.74%)

As of 08/14/2025 07:32 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Mereo BioPharma Group NASDAQ:MREO

$1.71 -0.02 (-1.16%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.71 0.00 (0.00%)

As of 04:13 AM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

scPharmaceuticals NASDAQ:SCPH

$4.95 +0.17 (+3.56%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$4.95 0.00 (0.00%)

As of 08/14/2025 07:39 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time